This site is intended for healthcare professionals
News

Two phase III and one phase II trials of concizumab in haemophilia A and B have been halted.- Novo Nordisk

Read time: 1 mins
Published:17th Mar 2020
Novo Nordisk announced that two clinical trials in the concizumab phase III programme (explorer7 and 8) and one clinical trial in the phase II programme (explorer5) have been paused. The three clinical trials were investigating concizumab prophylaxis treatment in haemophilia A and B patients regardless of inhibitor status. Consequently, no additional patients will be recruited, and further treatment of patients currently enrolled in the trials with concizumab will cease. The decision is a result of the occurrence of non-fatal thrombotic events in three patients enrolled in the ongoing phase III programme. Novo Nordisk and an independent Data Monitoring Committee are currently assessing the relevance of the events to the continuation of the programme and no conclusions have yet been made.
Condition: Haemophilia A + B
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.